↓ Skip to main content

Oncotarget

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach

Overview of attention for article published in Oncotarget, February 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter
9 X users
facebook
1 Facebook page
reddit
1 Redditor

Readers on

mendeley
21 Mendeley